SÃO PAULO—Brazilian health authority Anvisa authorized the restart Wednesday of clinical trials of China’s Sinovac coronavirus vaccine, one of the most advanced in the country, after suspending them earlier this week. Anvisa said it had evaluated new information about the “adverse event” on Oct. 29 that had triggered the suspension Monday, concluding it was safe to continue the tests. Brazil’s decision to suspend trials of the Chinese vaccine, which have been fiercely criticized by President Jair Bolsonaro, raised widespread concern among the country’s medical community. The vaccine’s own researchers, including the Butantan Institute, a respected São Paulo-based biomedical center, had disputed Anvisa’s decision, saying there had been no serious adverse reactions among volunteers and there was no reason to stop the trials. Local press reported that a volunteer had died, but from suicide. Anvisa said Wednesday that it had lifted the suspension after the Butantan Institute gave it further information about the October event, including a police report detailing the case. It said it hadn’t been given this information previously and had shut down the trials as a matter of precaution, acting in a purely technical manner. https://www.wsj.com/articles/brazil-to-resume-trials-of-chinas-sinovac-coronavirus-vaccine-11605106957
https://www.wsj.com/articles/brazil-to-resume-trials-of-chinas-sinovac-coronavirus-vaccine-11605106957